

**DOMESCO MEDICAL IMPORT EXPORT
JOINT STOCK CORPORATION**

**SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness**

**THE MEETING MINUTES
THE ANNUAL GENERAL MEETING OF SHAREHOLDERS IN 2026**

DOMESCO Medical Import Export JSC

No. 346 – Nguyen Hue Street – My Tra Ward –Dong Thap Province

*Business registration certificate No. 1400460395 issued by the Planning and Investment Department
of Dong Thap Province, first time on 30/12/2003 and registered for the 36th on 03/8/2025.*

Today, at 08:35 AM, 22nd April, 2026, the Annual General Meeting of Shareholders (AGM) in 2026 is held at the conference hall of DOMESCO Medical Import Export Joint Stock Corporation, No. 346 Nguyen Hue street, My Tra ward, Dong Thap province.

A/ PARTICIPANTS AND LEGALITY, VALIDITY OF THE GENERAL MEETING:

I/ PARTICIPANTS:

1. Shareholders and authorized shareholders who own DOMESCO shares as of the record date of 19th March, 2026 issued by Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh Branch.
2. Ms. Huynh Ngoc Minh Tran - Senior Audit Manager of Ernst & Young Vietnam Limited.
3. Board of Directors (BOD), Board of Supervisors (BOS), Board of Executives (BOE) and Chief Accountant:

1.	Mr. Nguyen Viet Phuong	- Chairman of BOD
2.	Ms. Luong Thi Huong Giang	- Vice Chairman of BOD cum General Director
3.	Mr. Nguyen Phi Thuc	- BOD Member
4.	Mr Nguyen Minh Duc	- BOD Independent Member
5.	Ms. Huynh Thi To Quyen	- Head of BOS
6.	Mr. Nguyen Duy Tung	- Vice General Director
7.	Ms. Pham Ngoc Tuyen	- Chief Accountant

II/ LEGALITY, VALIDITY OF THE MEETING:

1. Ms. Huynh Thi To Quyen – Head of BOS reports on the examination of shareholders' attendance:

- 1.1. The total shares of the Company is **34,727,465 shares**; total shares with the voting right is **34,727,465**.
 - 1.2. Total shareholders who were invited to attend the Meeting is **1,352** shareholders, standing for **34,727,465** shares with the voting right.
 - 1.3. Today, there are **45** shareholders and authorized shareholders in attendance, representing for **30,088,259** shares with the voting right, accounted for **86.64%** of the total shares with the voting right.
 - 1.4. All shareholders and representatives are eligible to attend in the Meeting.
2. Pursuant to the Enterprise Law 2020 and the Charter on organization and operation of DOMESCO Medical Import Export Joint Stock Corporation, the total shareholders and representatives at the AGM in 2026 of **86.64%** is higher than the minimum rate of 51% total shares with voting rights of the Company, therefore, the AGM in 2026 of is legal and valid.

B. MEETING CONTENTS:

I/ On behalf of the organizing committee, Mr. Dao Nam Phuong reports the Agenda for the General Meeting (*File enclosed*).

(Adopted by 100% shareholders and representatives at the Meeting)

II/ Notice for nomination and approval of the list of Presidium; Secretariat; The Voting Committee:

1. The Organizing Committee presents the number of Presidium is 03 people, Secretariat is 02 people, the Voting Committee is 03 people.

(Adopted by 100% shareholders and representatives at the meeting)

2. The Organizing Committee presents the list of Presidium, Secretariat, The Voting Committee:

2.1. The Presidium

- | | |
|-----------------------------|---|
| - Mr. Nguyen Viet Phuong | - Chairman of BOD |
| - Ms. Luong Thi Huong Giang | - Vice Chairman of BOD cum General Director |
| - Mr. Nguyen Duy Tung | - Vice General Director |

2.2. The Secretariat

- Ms. Luong Thi Bich Nhung
- Ms. Dao Thi Thuy Trang

2.3. The Voting Committee

- | | |
|-------------------------|-------------------------|
| - Mr. Tran Thanh Thuc | - Head of the Committee |
| - Mr. Tran Nguyen Cuong | - Member |
| - Ms. Vo Thi Kim Phung | - Member |

(Adopted by 100% shareholders and representatives at the meeting)

III/ Mr. Tran Thanh Thuc – The Head of Legal & Internal Control Department - representative of the Organizing Committee presents The working and voting regulations at the AGM in 2026 (File enclosed) .

(Adopted by 100% shareholders and representatives at the meeting)

IV/ CONTENTS OF THE GENERAL MEETING:

1. Mr. Nguyen Viet Phuong – BOD Chairman presents the report of Board of Directors on the performance in 2025. The orientation in 2026 (File enclosed).

2. Ms. Luong Thi Huong Giang - Vice Chairman of BOD cum General Director presents the report of BOE on production and business result of company in 2025. Production and business plan in 2026 (File enclosed).

*** Ms. Huynh Thi To Quyen – The Head of BOS reports additionally shareholders' attendance: Until 09:15 AM, 22/4/2026, there are 46 shareholders and authorized shareholders representating for 30,089,053 shares with the voting right, accounted for 86.64% of the total shares of the Company.**

3. Ms. Huynh Thi To Quyen – Head of BOS presents the report of BOS on performance in 2025. The orientation in 2026 (File enclosed).

4. Ms. Huynh Ngoc Minh Tran - Representatives of Ernst & Young Viet Nam Limited presents the report on the audited financial statement in 2025. The independent auditing company's report (File enclosed).

5. Mr. Nguyen Viet Phuong – BOD Chairman presents the proposal for the amendment of the Charter of DOMESCO Medical Import Export Joint Stock Corporation.

6. Ms. Pham Ngoc Tuyen – Chief Accountant presents the proposal of profit distribution in 2025 and profit distribution plan in 2026 (Files enclosed).

7. Ms. Huynh Thi To Quyen – Head of BOS presents the proposal for selecting the list of independent auditing companies in 2026 (File enclosed).

8. Mr. Nguyen Viet Phuong – Chairman presents the proposal on the removal of 01 BOS member who submitted letter of resignation (File enclosed).

(Adopted by 100% shareholders and representatives at the meeting)

9. Mr. Tran Thanh Thuc – The Head of Legal & Internal Control Department presents the regulations on electing additional members of the BOD, Supervisor for the term V (2024-2029) (File enclosed).

10. Mr. Nguyen Viet Phuong – Chairman presents the proposal for nomination & self-nomination to be BOD independent member, Supervisor of term V (2024-2029) (File enclosed).

(Adopted by 100% shareholders and representatives at the meeting)

11. Mr. Tran Thanh Thuc – The Head of the Voting Committee presents guidelines of voting and election.

*** On behalf of shareholders at the meeting, Head of BOS checked the ballot boxes and present that the ballot boxes are empty, fully sealed and eligible to vote.**



Shareholders carry out vote and election

12. Shareholders discuss, contribute ideas at the meeting

Shareholders' comments	Feedback of Presidium
Shareholder 1: Congratulations to the Company on completing assessment of the upgrade of the Non-betalactam plant in compliance with EU-GMP standards and obtaining the Certification. Could the Chairperson elaborate on the Company's capital mobilization plans for upcoming investments, and explain the reasons for the delay in implementing the EU-GMP project?	Currently, the company has sufficient internal capital to support its production, business operations and investments, so the company has no plans to raise external capital. The implementation of the EU - GMP project: depends on the company's business strategy at each stage and requires more time to research product plans for the EU export market and assess feasibility.
Shareholder 2 With the geopolitical instability in many regions of the World, could the Chairperson tell us your forecast for the company's long-term business sustainability and strategic direction for the next five years?	- Assessing the impact of geopolitical instability on the pharmaceutical field: Currently, the main hotspots include regional conflicts, supply chain disruption risks and trends of healthcare protectionism. Direct impacts on pharmaceutical enterprises: Raw material sources (API); Logistics costs and exchange rates; National health policies; Export market risks. - Ability to maintain long-term operations (5 years): Pharmaceutical companies are able to maintain stability, and even achieve growth, if they proactively restructure their supply chains and enhance their manufacturing capabilities, based on the following factors: + Demand for pharmaceuticals is essential and relatively inelastic to economic cycles. + Viet Nam is experiencing rapid population aging lead to the growth of long-term demand. + The Government prioritizes the development of the domestic pharmaceutical industry. + Ongoing manufacturing relocation trends. - Five-year strategic orientation: + Supply chain (top priority). + Upgrading manufacturing capabilities: investment in high standards (EU-GMP/ upgraded WHO-GMP). + Product portfolio. + Target markets: Domestic market serve as the foundation (hospital tender channel) and exports.

Shareholders' comments	Feedback of Presidium
In addition, has the consolidation from 63 provinces to 34 provinces affected the Company's business operations in recent times?	+ Risk management. - Short-term impact: There will be certain impacts on business operations due to: + Changes in administrative area, disrupt the distribution system and sales staffs. + Changes in relevant authorities: Departments of Health, hospitals. + Costs and time are incurred relating to restructure sales areas and complete the changing procedures for the new administrative areas. - Medium to long-term impact: Positive impacts are expected due to: + Streamline administrative agencies, more convenient in working with regulatory authorities. + Optimize the distribution system, improve operational efficiency.
Shareholder 3 Could the Chairman provide information on the Company's sales channels and the revenue proportion of each channel?	- Hospital channel (ETC): through participation in tendering across bidding groups. - OTC channel - direct distribution by the Company's branches. - Health supplements products distributed through e-commerce channels.
Shareholder 4: The Company stated in your report that profit has not met expectations due to the impact of exchange rates and logistics costs. Why does not the Company utilize third-party logistics services to reduce costs and improve delivery time, thereby minimizing cancellation of orders due to prolonged delivery time?	- The logistics issue mentioned in the report relates to the transportation of imported raw materials and packaging for production, which has been affected by escalating geopolitical tensions, leading to increased freight costs. - The transportation of drugs is carried out by the Company's branches, and means of transport must comply with Good Distribution Practice (GDP) standards. The branches have detailed delivery schedules to facilitate for placing orders by customers and in alignment with the delivery schedules of the branches.

13. On behalf of the Voting Committee, Mr. Tran Thanh Thuc discloses the vote counting minutes with the following result:

1- The report of BOD on the performance in 2025. The orientation in 2026.

Contents	Favor	Against	Abstention	Invalid	TOTAL
Number of shares	30,089,053				30,089,053
%	100.0	0.0	0.0	0.0	100

2- The report of BOE on production and business result of company in 2025. Production and business plan in 2026.

Contents	Favor	Against	Abstention	Invalid	TOTAL
Number of shares	30,089,053				30,089,053
%	100.0	0.0	0.0	0.0	100

3- The report of BOS on performance in 2025. The orientation in 2026.

Contents	Favor	Against	Abstention	Invalid	TOTAL
Number of shares	30,089,053				30,089,053
%	100.0	0.0	0.0	0.0	100

4- The report on the audited financial statement in 2025. The independent auditing company's report.

Contents	Favor	Against	Abstention	Invalid	TOTAL
Number of shares	30,089,053				30,089,053
%	100.0	0.0	0.0	0.0	100

5- Proposal for the amendment of the Charter of DOMESCO Medical Import Export Joint Stock Corporation.

Contents	Favor	Against	Abstention	Invalid	TOTAL
Number of shares	30,089,053				30,089,053
%	100.0	0.0	0.0	0.0	100

6- The proposal of profit distribution in 2025 and profit distribution plan in 2026.

Contents	Favor	Against	Abstention	Invalid	TOTAL
Number of shares	18,034,586	12,054,467			30,089,053
%	59.9	40.1	0.0	0.0	100

7- The proposal for selecting the list of independent auditing companies in 2026..

Contents	Favor	Against	Abstention	Invalid	TOTAL
Number of shares	30,089,053				30,089,053
%	100.0	0.0	0.0	0.0	100

(Attached Minutes of Vote Counting)

14. On behalf of the Voting Committee, Mr. Tran Thanh Thuc discloses the election counting minutes with the following result:

*** The results of additional election for BOS member for the term V (2024-2029)**

- Number of invalid votes: **0 votes**, representing for **0** shares, proportion: **0%** of the total shares with the voting right at the Meeting.
- Number of valid votes: **46 votes**, representing for **30,089,053** shares, proportion: **100%** of the total shares with the voting right at the Meeting.

No.	Full name	Vote of confidence	
		Number of shares	Proportion (%)
1	Ms. Nguyen Kim Ngoc	30,084,053	99.98

*** List of elected Supervisor for the term V (2024-2029):**

1	Ms. Nguyen Kim Ngoc
---	---------------------

(File enclosed)

Article 15. The additional election for the BOD independent member for the term V (2024-2029)

The AGM authorizes BOD for the term V to continue searching candidates who meet the criteria for independent members of the BOD, reporting to the AGM to elect additional members to the BOD in accordance with provision of law and Company Charter.

The Minutes of the Annual General Meeting of shareholders in 2026 of DOMESCO Medical Import Export Joint Stock Corporation dated 22nd April, 2026 serve as the legal basis for issuing the Resolution of the Annual General Meeting of Shareholders in 2026 of DOMESCO Medical Import Export Joint Stock Corporation.


This Minutes disclosed at 12:00 PM, 22nd April, 2026 and approved by 100% shareholders and representatives at the Meeting./.

SECRETARIAT

1/ Ms. Luong Thi Bich Nhung



2/ Ms. Dao Thi Thuy Trang



**ON BEHALF OF THE ANNUAL GENERAL
MEETING OF SHAREHOLDER IN 2026
DOMESCO MEDICAL IMPORT EXPORT JSC
CHAIRMAN OF THE MEETING**



Nguyen Viet Phuong

[NOTICE: This version is a translation of Vietnamese language original for convenience purpose only, and in the event of discrepancy, the Vietnamese language original shall prevail].